Akero Therapeutics (AKRO) Expected to Announce Earnings on Friday

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Friday, May 9th. Analysts expect Akero Therapeutics to post earnings of ($1.00) per share for the quarter.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, analysts expect Akero Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Akero Therapeutics Trading Up 1.8 %

AKRO stock traded up $0.77 during trading on Wednesday, reaching $42.79. 980,502 shares of the stock traded hands, compared to its average volume of 882,612. The business's 50 day moving average price is $41.36 and its 200-day moving average price is $37.28. The firm has a market capitalization of $3.41 billion, a PE ratio of -11.41 and a beta of -0.12. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics has a 52-week low of $17.86 and a 52-week high of $58.40.

Analyst Ratings Changes

AKRO has been the topic of a number of recent research reports. Canaccord Genuity Group lifted their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. UBS Group upped their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Citigroup raised their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Bank of America upgraded Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Finally, HC Wainwright boosted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $76.29.

Insiders Place Their Bets

In related news, Director G. Walmsley Graham bought 91,309 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were acquired at an average price of $44.75 per share, for a total transaction of $4,086,077.75. Following the purchase, the director now owns 1,091,309 shares in the company, valued at $48,836,077.75. This trade represents a 9.13 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Andrew Cheng sold 30,000 shares of Akero Therapeutics stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $52.73, for a total value of $1,581,900.00. Following the completion of the transaction, the chief executive officer now owns 686,062 shares of the company's stock, valued at $36,176,049.26. This trade represents a 4.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 198,708 shares of company stock worth $8,673,699 in the last three months. 7.94% of the stock is owned by insiders.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.